ImageneBio (NASDAQ:IMA) Issues Earnings Results, Misses Estimates By $0.25 EPS

ImageneBio (NASDAQ:IMA) announced its quarterly earnings data on Thursday. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.25), FiscalAI reports.

ImageneBio Stock Down 10.5%

Shares of NASDAQ:IMA traded down $0.62 during midday trading on Friday, hitting $5.29. The stock had a trading volume of 75,284 shares, compared to its average volume of 1,023,482. ImageneBio has a fifty-two week low of $3.94 and a fifty-two week high of $18.00. The company has a market capitalization of $56.34 million, a P/E ratio of -0.66 and a beta of 0.73. The company’s 50-day moving average price is $5.71 and its 200-day moving average price is $6.60.

Hedge Funds Weigh In On ImageneBio

Institutional investors have recently added to or reduced their stakes in the stock. Deep Track Capital LP acquired a new position in shares of ImageneBio during the third quarter worth $7,160,000. Blue Owl Capital Holdings LP raised its position in shares of ImageneBio by 52.3% during the fourth quarter. Blue Owl Capital Holdings LP now owns 823,785 shares of the company’s stock worth $5,684,000 after acquiring an additional 282,861 shares during the last quarter. Atlas Venture Life Science Advisors LLC acquired a new position in shares of ImageneBio in the 3rd quarter worth approximately $3,079,000. Vanguard Group Inc. acquired a new position in ImageneBio in the third quarter valued at $1,902,000. Finally, BML Capital Management LLC boosted its position in shares of ImageneBio by 13.4% during the 1st quarter. BML Capital Management LLC now owns 200,730 shares of the company’s stock valued at $1,004,000 after purchasing an additional 23,704 shares in the last quarter. 75.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded shares of ImageneBio from a “hold” rating to a “sell” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, ImageneBio presently has a consensus rating of “Hold” and a consensus price target of $26.50.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.